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OBJECTIVE—To determine whether middle-aged and older
individuals with impaired fasting glucose (IFG), but no clinical
evidence of cardiovascular disease, exhibit abnormal changes in
proximal thoracic aortic stiffness or left ventricular (LV) mass
when compared with healthy counterparts.
RESEARCH DESIGN AND METHODS—From the Multi-
Ethnic Study of Atherosclerosis, 2,240 subjects with normal
fasting glucose (NFG), 845 with IFG, and 414 with diabetes, all
aged 45 to 85 years and without preexisting coronary artery
disease, underwent MRI determinations of total arterial and
proximal thoracic aortic stiffness and LV mass. The presence or
absence of other factors known to inﬂuence arterial stiffness was
assessed.
RESULTS—After adjustment for clinical factors known to mod-
ify arterial stiffness, proximal thoracic aortic stiffness was not
increased in those with IFG compared with those with NFG
(1.90  0.05 versus 1.91  0.04 10
3 mmHg
1, respectively, P 
0.83). After accounting for clinical factors known to inﬂuence LV
mass, LV mass was increased in those with diabetes relative to
those with NFG (150.6  1.4 versus 145.8  0.81 g, P  0.0009)
but not in those with IFG in comparison with NFG (145.2  1.03
versus 145.8  0.81 g, P  0.56).
CONCLUSIONS—Middle-aged and older individuals with the
pre-diabetes state of IFG do not exhibit abnormal proximal
thoracic distensibility or LV hypertrophy relative to individuals
with NFG. For this reason, an opportunity may exist in those
with IFG to prevent LV hypertrophy and abnormal aortic stiffness
that is observed in middle-aged and older individuals with
diabetes. Diabetes 58:946–953, 2009
I
ndividuals with diabetes exhibit increased arterial
stiffness that is associated with future cardiovascu-
lar morbidity and mortality, peripheral arterial dis-
ease, impaired myocardial function, left ventricular
(LV) hypertrophy, and congestive heart failure (1–6). For
those with diabetes, different clinical sequelae occur de-
pending on the location of abnormal stiffening within the
arterial system (7–9). For example, abnormal proximal
thoracic aortic stiffness contributes to abnormal ventricu-
lar vascular coupling, LV hypertrophy and dysfunction,
and exercise intolerance (10). In peripheral arteries, ab-
normal arterial stiffness is associated with endothelial
dysfunction and arteriosclerosis (11,12).
Individuals with impaired fasting glucose (IFG) exhibit a
higher rate of cardiovascular events compared with those
with normal fasting glucose (NFG) (9,13–15). Importantly,
however, studies to date (7,8) have not clariﬁed whether
subjects with IFG exhibit abnormal arterial stiffness, es-
pecially within the proximal thoracic aorta, that in other
populations is associated with cardiac dysfunction and
exercise intolerance (10).
To determine if middle-aged and older individuals with
IFG but no clinical cardiovascular disease exhibit abnor-
mal changes in arterial stiffness, including the proximal
thoracic aorta, compared with healthy counterparts, we
analyzed MRI measures of arterial stiffness in participants
from the Multi-Ethnic Study of Atherosclerosis (MESA).
We hypothesized that total arterial and proximal thoracic
aortic stiffness would be altered in participants with IFG
as well as those with diabetes when compared with
individuals with NFG. We also sought to determine if LV
mass, which is directly inﬂuenced by proximal thoracic
aortic stiffness, was abnormal in individuals with IFG and
diabetes.
RESEARCH DESIGN AND METHODS
Study subjects. The recruitment criteria of the individuals in MESA have
been previously described (16). MESA is a large population-based sample of
men and women from four ethnic groups (white, black, Hispanic, and
Chinese) aged 45 to 84 years and without clinical cardiovascular disease. A
total of 5,004 MESA participants received cardiovascular MRI studies, of
whom 3,499 participants had examinations of proximal thoracic aortic stiff-
ness. Institutional review committees in each participating site approved the
study, and all participants provided written informed consent.
Participants in this study were characterized using criteria established by
the American Diabetes Association into one of three groups using their fasting
plasma glucose level (17). This included those with NFG (fasting glucose level
of 100 mg/dl), IFG (fasting glucose level of 100–125 mg/dl), and diabetes
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946 DIABETES, VOL. 58, APRIL 2009(fasting glucose level of 126 mg/dl). Participants with a history of diabetes
(with or without treatment) were classiﬁed into the diabetes group regardless
of their fasting glucose level. Blood pressure was measured after 5 min of rest
with sequential Dinamap measures, with a 5-min rest period between each
sampling. Hypertension was deﬁned by a systolic blood pressure (sBP) of 140
mmHg or greater or a diastolic blood pressure (dBP) of 90 mmHg or greater
that occurred as the average of the second and third Dinamap measures on the
initial clinic visit. Participants were also identiﬁed as hypertensive if they
self-reported the presence of hypertension and they used any antihypertensive
medication. Cigarette smoking was deﬁned as ever smoked (100 cigarettes
in one’s lifetime).
Magnetic resonance imaging technique. Using MRI, two previously de-
scribed noninvasive measures of cardiovascular stiffness were obtained and
used as the primary stiffness outcomes for the study. The ﬁrst was assessment
of proximal thoracic aortic distensibility: a measure of cardiac cycle–depen-
dent changes in aortic area after accounting for brachial pulse pressure and
resting vessel area (10). The second was an assessment of total cardiovascular
stiffness that involved determination of change in LV stroke volume after
accounting for brachial pulse pressure. In addition to these measures, LV mass
was measured (3).
MRI studies were performed at six participating sites using 1.5-Tesla
magnets (three from General Electric Medical Systems [Waukesha, WI] CV/i or
LX platforms and three from Siemens Medical Solutions [Erlangen, Germany]
Symphony or Sonata platforms). Participants were scanned in a supine
position using a torso phased-array coil placed anteriorly and posteriorly and
equipment approved for the MRI environment.
LV parameters. The left ventricle was imaged according to previously
published techniques in short axis slices starting from the base at the mitral
valve plane to the apex (18). According to previously published methods (18),
LV stroke volume was determined in each individual for use in the calculation
of total vascular stiffness (19–21). For LV volume and mass determinations,
the epi and endocardial border of each slice was planimetered manually at end
diastole and end systole, and volumes were calculated by summation (Simp-
son’s rule) as previously described. The LV ejection fraction was calculated
from the ratio of the difference between LV end-diastolic and end-systolic
volumes relative to end-diastolic volumes. The LV mass was calculated from
summation of the LV myocardial volumes during end diastole in each short
axis slice at end diastole and multiplied 1.05. The variability of the MRI
readings was determined from a set of 155 duplicate readings to be 4.77% (95%
CI 3.63–6.02) for end-diastolic volume and 11.61% (9.55–13.71) for end-systolic
volume (18).
Total and proximal thoracic aortic stiffness. Images of the proximal
thoracic aorta were obtained axially at the level of the main pulmonary artery
identiﬁed on a sagittal scout image. Imaging parameters included a phase-
contrast gradient-echo sequence with a 34-cm ﬁeld of view, a 10-ms repetition
time, a minimal full echo time, a 20° ﬂip angle, an 8-mm-thick slice, a 256  224
matrix, 20 phases per cardiac cycle, two excitations, a 32-kHz bandwidth, and
a velocity encoding of 150 cm/s. Brachial arterial pressure was measured
noninvasively with a nonferromagnetic arm blood pressure cuff and recorded
before and after at the time of the phase-contrast acquisition and then
averaged to derive mean values. The pulse pressure was calculated from the
difference between sBP and dBP.
Determination of stiffness in the ascending thoracic aorta was accom-
plished by measuring aortic distensibility according to previously published
methods using the following formula whereby the area of the ascending aorta
was identiﬁed from the phase-contrast, gradient-echo images throughout all
phases of the cardiac cycle (10,22):
Aortic distensibility (10
3 mmHg  (1)  [maximal aortic area  minimal
aortic area] [brachial pulse pressure  minimal aortic area].
To examine total vascular stiffness, the total arterial compliance was
calculated according to the following previously published formula (Fig. 1)
(19–21):
Total arterial compliance (ml  mmHg
1)  LV stroke volume/pulse
pressure.
Also, the inverse of total arterial compliance pulse pressure (PP)–to–stroke
volume (SV) ratio was indexed for body surface area (PP/SVi) to account for
potential differences in body size that may inﬂuence arterial stiffness. Total
arterial elastance was determined using the change in LV SV/mean arterial
pressure.
Results were expressed as means  SE of the estimate unless stated
otherwise. Descriptive statistics were ﬁrst examined stratiﬁed by fasting
glucose status (NFG, IFG, and diabetes). Next, comparisons across the three
levels of fasting blood glucose were made with an ANCOVA approach using
PROC GLM in SAS 9.1 (SAS Institute, Cary, NC). We ﬁt a series of progres-
sively more complex models to examine the relationship of glucose tolerance
status (coded as a three-level class variable: NFG, IFG, and diabetes) and two
outcomes of interest (total arterial and proximal thoracic aortic stiffness).
There was a total of three models ﬁt: model 1, adjusted for age (continuous
variable), race/ethnicity, sex, and participating site; model 2, adjusted for
variables from model 1 along with sex, race/ethnicity, age, site, weight, total
cholesterol, high-density lipoproteins, triglycerides, mean arterial pressure,
waist-to-hip ratio, statin therapy, smoking, and estimated glomerular ﬁltration
rate; model 3, adjusted for variables from model 2 and hypertension (deﬁned
as the use of blood pressure medicine or an sBP 140 mmHg or dBP 90
mmHg on the ﬁrst clinic examination). For each of these models, we ﬁrst
examined the overall main effect for glucose tolerance status. When this was
signiﬁcant, two speciﬁc pairwise comparisons among the three groups (NFG
versus IFG and NFG versus diabetes) were examined using two-sample t tests
based on the adjusted mean values from the model (using the LSMEANS
option in PROC GLM).
RESULTS
Of the 3,499 subjects (mean age 61  10 years), 1,596 (46%)
were men, 1,468 (42%) were white, 1,049 (30%) were black,
385 (11%) were Hispanic, and 597 (17%) were Chinese. As
shown in Table 1, compared with those with NFG, those in
the IFG group exhibited a higher BMI, waist-to-hip ratio,
sBP, and triglyceride level as well as a lower HDL choles-
FIG. 1. Formula for determining magnetic resonance imaging measures of total vascular stiffness (left panel) and proximal thoracic aortic
stiffness (right panel). The left panel shows portions of the vascular system encompassed by the stiffness measure. In the right panel, coronal
and transaxial views of the LV ascending thoracic aorta are provided. The circle demarcates the boundary of the ascending aorta (Ao), from which
dimensions are determined by the calculation of proximal thoracic aortic stiffness. Total arterial stiffness  LV stroke volume/brachial artery
pulse pressure. Proximal thoracic aortic stiffness  (area aorta end systole  area aorta end diastole)/(brachial artery pulse pressure  area
aorta end diastole).
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DIABETES, VOL. 58, APRIL 2009 947terol level. As shown in Table 1, similar differences were
also present in those with diabetes. When compared,
subjects with NFG were younger and more frequently
women and/or white.
Across the study population, total and proximal thoracic
aortic stiffness was not increased in those with NFG
compared with those with IFG or diabetes (unadjusted
data; Table 2). Also, arterial elastance (deﬁned from the
mean arterial pressure rather than pulse pressure/the LV
stroke volume) was different in NFG (1.06  0.01) relative
to IFG (1.12  0.01; P  0.0005) or diabetic (1.14  0.02;
P  0.007) participants. The differences in total vascular
stiffness between subjects with NFG and IFG or diabetes
persisted after adjustment for age, race/ethnicity, sex, and
study site (model 1, Table 2). We examined sex by glucose
status (NFG, IFG, and diabetes) interactions for all stiff-
ness measures and found none to be signiﬁcant (all with
P  0.15).
After adjusting for the variables included in model 1 of
Table 2, the difference in proximal thoracic aortic stiffness
remained present between NFG and diabetic subjects but
not between NFG and IFG subjects (model 2, Table 2; Figs.
2 and 3). Age was the variable most associated with the
difference in proximal thoracic aortic stiffness observed
between subjects with NFG and IFG.
After the adjustments for model 3, total vascular stiff-
ness remained increased in those with IFG compared with
those with NFG (Fig. 2). However, the proximal thoracic
aortic stiffness in those with IFG remained similar to that
of those with NFG (Fig. 3). Across the study, the LV
unadjusted mass in those with IFG or diabetes was in-
creased when compared with those with NFG (150.8  1.3
versus 140.4  0.8 g, P  0.0001, and 158.7  1.9 versus
140.4  0.8 g, P  0.0001, respectively). When compared
with individuals with NFG, and after accounting for the
same covariates in Figs. 2 and 3, LV mass was increased in
TABLE 2
Multivariate analysis of total arterial stiffness and proximal thoracic aortic stiffness among those with normal fasting glucose,
impaired fasting glucose, and diabetes
Total vascular stiffness Proximal thoracic aortic stiffness
(ml/mmHg) (10
10 mmHg
1)
NFG IFG Diabetes NFG IFG Diabetes
Unadjusted 1.87  0.01 1.73  0.02† 1.58  0.03† 1.94  0.03 1.77  0.05* 1.45  0.06†
Model 1 1.84  0.01 1.74  0.02† 1.66  0.03† 1.90  0.03 1.87  0.04 1.64  0.06†
Model 2 1.86  0.01 1.78  0.02† 1.70  0.03† 1.92  0.04 1.90  0.05 1.66  0.06†
*P  0.01 compared with NFG. †P  0.001 compared with NFG. Hypertension is deﬁned by systolic blood pressure 140 mmHg or diastolic
blood pressure 90 mmHg that occurred as the average of the second and third Dinamap measures on the initial clinic visit. Model 1 adjusted
for age, race/ethnicity, sex, and participating site. Model 2 adjusted for variables from model 1 and sex, race/ethnicity, age, site, weight, total
cholesterol, HDL cholesterol, triglycerides, mean arterial pressure, waist-to-hip ratio, statin therapy, smoking, and estimated glomerular
ﬁltration rate.
TABLE 1
Baseline characteristics
NFG IFG Diabetes
n 2240 845 414
Age (years) 59.4  9.9 62.2  9.9* 63.5  9.4*
Male (%)† 926 (41) 459 (54) 211 (51)
Race/ethnicity (%)†
White 1,043 (47) 324 (38) 101 (24)
Black 599 (27) 260 (31) 190 (46)
Chinese 230 (10) 109 (13) 46 (11)
Hispanic 368 (16) 152 (18) 77 (19)
Height (cm) 166.6  9.9 167.6  9.9* 166.7  10.3
Weight (kg) 75.6  15.7 81.3  16.5* 83.0  16.4*
BMI (kg/m
2) 27.1  4.7 28.8  5.1* 29.8  5.3*
Waist circumference (cm) 94  13 100  13* 102  13*
Waist-to-hip ratio 0.90  0.09 0.94  0.07* 0.96  0.06*
Systolic blood pressure (mmHg) 122  20 128  21* 132  22*
Diastolic blood pressure (mmHg) 71  10 73  11* 73  10*
Hypertension (%) 776 (35) 413 (49) 271 (65)
Antihypertension medications (%) 535 (24) 325 (38) 219 (53)
Total cholesterol (mg/dl) 194  33 194  34 190  37*
Triglycerides (mg/dl) 116  63 131  66* 139  74*
LDL cholesterol (mg/dl) 117  30 119  30 113  34*
HDL cholesterol (mg/dl) 54  15 49  14* 48  14*
Fasting glucose (mg/dl) 90  6 107  6* 150  50*
Creatinine (mg/dl) 0.94  0.20 0.97  0.22 0.97  0.57
Calcium channel blockers 197 (10) 139 (16) 80 (19)
Nitrates 4 (0.2) 1 (0.1) 0 (0)
Data are means  SD. *P  0.05 compared with NFG. †P  0.05 among groups.
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0.007) but not in those with IFG (145.2  0.9 versus
144.9  1.0 g, P  not signiﬁcant) (Fig. 4).
To determine if the variables in the numerators (LV SV
for total and aortic area for proximal thoracic aorta) or
denominators (PP for both) of our measures of stiffness
were more inﬂuential in accounting for our results, we
performed additional analyses adjusting the model 3 (re-
sults graphed in Figs. 2–4) stiffness measure for the
variables in the numerator and denominator. After adjust-
ing for LV SV, the total stiffness was 1.82  0.01 ml/mmHg
for NFG, 1.79  0.02 ml/mmHg for IFG (P  0.004 from
NFG), and 1.74  0.02 ml/mmHg for diabetes (P  0.0005
from NFG); and after adjusting for PP, the total stiffness
was 1.85  0.01 ml/mmHg for NFG, 1.78  0.01 ml/mmHg
for IFG (P  0.0001 from NFG), and 1.77  0.02 ml/mmHg
for diabetes (P  0.0007 from NFG). After adjusting for the
cardiac cycle–dependent change in aortic area, proximal
thoracic aortic stiffness was 1.89  0.03 10
3 mmHg
1 for
NFG, 1.90  0.04 10
3 mmHg
1 for IFG (P  0.74 from
NFG), and 1.81  0.05 10
3 mmHg
1 for diabetes (P  0.14
from NFG); and after adjusting for PP, proximal
thoracic aortic stiffness was 1.91  0.04 10
3 mmHg
1
for NFG, 1.90  0.05 10
3 mmHg
1 for IFG, and 1.68 
0.06 10
3 mmHg
1 for diabetes (P  0.0007 from NFG).
Because many of the differences noted between the groups
in model 3 remain (Figs. 2–4), the results of these adjust-
ments suggest that both values in the numerators and
denominators were important for inﬂuencing the differ-
ences or similarities in vascular stiffness noted between
the groups assessed in this study.
We tested for interactions between sex and measures of
vascular stiffness by glucose group (NFG, IFG, and diabe-
tes) and found them all to be nonsigniﬁcant. For vascular
stiffness, the P value was 0.58; for LV end-diastolic mass, it
was 0.17; and for aortic distensibility (stiffness), it was
FIG. 2. Comparison of adjusted total arterial stiffness of those with IFG or diabetes (DM) and those exhibiting NFG. *Adjusted for recruited age,
race/ethnicity, sex, site, weight, total cholesterol, HDL cholesterol, triglycerides, mean arterial pressure, waist-to-hip ratio, statin therapy,
smoking, estimated glomerular ﬁltration rate, and hypertension.
FIG. 3. Comparisons of adjusted proximal aortic stiffness of those with IFG or diabetes (DM) and those exhibiting NFG. *Adjusted for recruited
age, race/ethnicity, sex, site, weight, total cholesterol, HDL cholesterol, triglycerides, mean arterial pressure, waist-to-hip ratio, statin therapy,
smoking, estimated glomerular ﬁltration rate, and hypertension.
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were no sex differences in the relation between glucose
group and outcomes.
To determine if the ﬁndings relating to proximal aortic
distensibility were inﬂuenced by the resting arterial diam-
eter or the geometry of the aorta, we measured aortic
compliance in our three patient groups. After adjusting for
variables in model 3 (Figs. 2–4), aortic compliance was
1.48  0.02, 1.44  0.03, and 1.32  0.04 in those with NFG,
IFG, and diabetes, respectively. Like with aortic distensi-
bility, compliance in participants with diabetes was re-
duced compared with that found in those with NFG (P 
0.0001) but not in those with IFG relative to those with
NFG (P  0.22).
Of the 414 subjects with diabetes, 256 provided data on
the duration of receipt of oral or insulin therapy. The
duration of treatment ranged from 0 (current year) to 41
years, with a median of 6 years. As shown in Fig. 5, total
and proximal thoracic aortic stiffness was worse for those
treated for the median of 6 years or longer as opposed to
less than the median of 6 years. Also, LV mass trended
higher in those treated longer than 6 years for diabetes.
In addition to measuring total arterial elastance, a
stiffness measure dependent on mean arterial pressure
rather than PP, we also performed analysis adjusting our
models for measures of mean arterial pressure rather than
the prespeciﬁed diagnosis of hypertension. The differences
and similarities between our participant groups persisted
using mean arterial pressure as a covariate.
The use of statin therapy was 14.2% across the study
population (11% of NFG, 16% of the IFG, and 26% of the
diabetes participants). This may have inﬂuenced the lower
LDL cholesterol level observed in our study population.
After adjusting the total and proximal aortic stiffness for
statin use (model 2, Table 2), differences between groups
persisted.
Often, patients with diabetes or IFG exhibit features of
the metabolic syndrome. We performed analyses to deter-
mine if the pressure of the metabolic syndrome would
change the relations we observed in total arterial stiffness
and proximal thoracic stiffness among our three groups.
After accounting for the metabolic syndrome, all pairwise
comparisons between NFG and diabetes or IFG remained
unchanged.
FIG. 4. Comparison of adjusted left ventricular mass of those with IFG or diabetes (DM) and those exhibiting NFG. *Adjusted for recruited age,
race/ethnicity, sex, site, weight, total cholesterol, HDL cholesterol, triglycerides, mean arterial pressure, waist-to-hip ratio, statin therapy,
smoking, estimated glomerular ﬁltration rate, and hypertension.
FIG. 5. Mean  SE of the estimates of total and proximal thoracic aortic stiffness and LV mass for participants with diabetes treated longer than
6 years (f) and 6 years or less (). *Adjusted for recruited age, race/ethnicity, sex, site, weight, total cholesterol, HDL cholesterol, triglycerides,
mean arterial pressure, waist-to-hip ratio, statin therapy, smoking, estimated glomerular ﬁltration rate, and hypertension.
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Abnormally stiffened arteries are present in individuals
with diabetes and are associated with an increase in
cardiovascular events, LV afterload, and exercise intoler-
ance (1,4,9). In this study, we sought to determine if
individuals with IFG exhibited abnormal stiffening of the
arterial tree (including the proximal thoracic aorta) that in
studies of individuals with diabetes is associated indepen-
dently with adverse cardiovascular events. There are two
important ﬁndings in this study: Total vascular stiffness is
worse in subjects with IFG compared with those with
NFG. This ﬁnding is true regardless of age, sex, ethnicity,
or other factors associated with abnormal vascular stiff-
ening (Table 2; Fig. 2). After adjustment for factors known
to inﬂuence vascular stiffness, proximal thoracic aortic
stiffness and LV mass are similar in individuals with IFG
and NFG (Figs. 3 and 4). In patients with diabetes,
however, both proximal thoracic aortic stiffness and LV
mass are elevated (Figs. 3 and 4).
In this cross-sectional analysis of the data from the
MESA cohort study, subjects with IFG demonstrated
higher BMI, blood pressure, total cholesterol, and serum
triglyceride compared with those with NFG. These are all
clinical features of the metabolic syndrome, which affects
47 million Americans and is associated with hyperinsulin-
emia and insulin resistance (23). After adjusting for these
variables, the subjects with IFG demonstrated greater
total arterial stiffness than those with NFG. The data in
this study indicate that mild elevations of blood glucose
adversely affect cardiovascular stiffening independent of
other common cardiovascular risk factors associated with
the metabolic syndrome.
There are several mechanisms by which total arterial
stiffness becomes elevated in individuals with IFG or
diabetes. Elevations in blood glucose lead to the formation
and deposition of advanced glycation end products
(24,25). These products promote the crosslinking of colla-
gen that stiffens the structural components of the arterial
wall (24,25). Diabetes also promotes increased lipid oxi-
dation, vasoconstriction, tissue remodeling, low-grade in-
ﬂammation, atherosclerosis, and sympathetic nervous
system activation (26,27). Many of these processes inhibit
endothelial nitric oxide synthase, which consequently im-
pairs peripheral endothelial function and adversely effects
vascular stiffness (24,25,28–30).
It is important to note that some of the mechanisms by
which arteries stiffen after exposure to elevations in blood
glucose occur rapidly, whereas others require more time
to develop. For example, peripheral arterial endothelial
function is known to deteriorate 1 h after high glucose oral
intake (31). There is also emerging evidence that postpran-
dial hyperglycemia is associated with the development of
atherosclerosis, which in turn heightens peripheral arterial
stiffness (32). It is not surprising that those with IFG or
diabetes exhibit abnormal total vascular stiffness of the
entire vascular tree because both IFG and diabetes ad-
versely impact endothelial function, atherosclerosis, and
vasomotor tone, each of which inﬂuences peripheral ar-
tery stiffness after a short duration of exposure.
The use of MRI in this study provided the opportunity to
assess proximal thoracic aorta stiffness. The proximal
thoracic aorta stiffens abnormally in those with diabetes
(27), and several studies have identiﬁed the adverse im-
pact of proximal thoracic aortic stiffness on LV perfor-
mance and exercise capacity in those with diabetes and
those with heart failure (10,22).
Our group and others have demonstrated an indepen-
dent relationship between proximal thoracic aortic stiff-
ness and increased LV mass and exercise intolerance in
individuals with heart failure (10,22).
The results of this study indicate that proximal thoracic
aortic stiffness, a stimulus for increased LV hypertrophy
and diminished LV performance, is not dissimilar in those
with IFG and NFG. In addition, those subjects with IFG
had no increase in LV mass after accounting for other
conditions known to inﬂuence LV mass. Our results par-
allel those of others indicating absence of a relationship
between IFG and LV dysfunction or hypertrophy (33).
These data indicate that regardless of sex, ethnicity, or
age, those with IFG do not exhibit increased proximal
thoracic aortic stiffness, and they suggest that prolonged
exposure to high serum levels of glucose are necessary to
enhance stiffening of the proximal thoracic aorta. This
stands to reason given that prolonged exposure to higher
levels of glucose increases the opportunity for advanced
glycation end products to facilitate a higher number of
crosslinks within the collagen of the wall of the central
aorta.
Another possible mechanism by which stiffness in the
ascending aorta may not be increased in those with IFG
relates to the effects of atherosclerotic plaque burden.
Diabetes is one of the most important risk factors for the
presence of aortic atherosclerotic plaque, and a positive
association has been shown between the presence of
atherosclerotic plaque and arterial stiffness (34). Underly-
ing inﬂammation may be less operative in patients with
IFG. Scuteri et al. reported that increased large arterial
stiffness and impaired endothelial function were found in
the normotensive normoglycemic ﬁrst-degree relatives of
patients with diabetes independent of the presence of the
metabolic syndrome (35). These data suggest that mecha-
nisms other than the level of serum glucose such as
endothelial dysfunction or low-grade inﬂammation may
affect the stiffness of proximal thoracic aorta (36,37).
Sengstock and associates (38) also demonstrated that
insulin resistance was an important factor in the stiffening
of arteries. Potential mechanisms mediating this factor
include endothelial dysfunction and/or vascular smooth
muscle proliferation.
To address the relation between prolonged exposure to
high serum levels of glucose and arterial (both total and
proximal thoracic aortic) stiffness, we reviewed the results
of MESA participants who responded to the question of
duration of diabetes treatment. We were able to assess the
relation among treatment duration, central aortic stiffness,
and LV mass. As shown in Fig. 5, after accounting for
variables known to inﬂuence proximal thoracic aortic
stiffness, total and aortic stiffness were worse for individ-
uals treated for diabetes longer than 6 years. There was
also a strong trend toward an increase in LV mass for
those treated for diabetes longer than a median of 6 years.
What are some of the clinical applications of our study
results? Those with IFG do not exhibit abnormalities of
proximal thoracic aortic stiffness to the magnitude ob-
served by those with diabetes. Data to date indicate that
stiffening in the central aorta has hemodynamically detri-
mental effects on the cardiovascular system and a strong
association with increased cardiovascular mortality. This
may be one of the possible explanations for why those
with IFG have no increase in LV mass and perhaps lower
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diabetes. Preventing pre-diabetes states from developing
into diabetes theoretically could prevent stiffening of
central aorta and associated adverse clinical sequela.
Therapies designed to reduce stiffness in the proximal
thoracic aorta may differ for middle-aged and older indi-
viduals with IFG versus diabetes. Studies involving the
collagen crosslink breaker thiazolidinedione for the pur-
pose of attenuating aortic stiffness and regressing LV
hypertrophy are underway in patients with heart failure
(39,40). In the absence of other clinical conditions known
to stiffen the aorta, older individuals with IFG do not
exhibit stiff aortas, so suitability for participation in these
studies may differ.
Previously, in primary prevention strategies, statin ther-
apy has been shown to reduce cardiovascular events (41),
improve endothelial function, and regress atherosclerotic
plaques in the aorta (42,43) in patients with diabetes. In
patients with diabetes or IFG and concomitant hypercho-
lesterolemia, guidelines exist for prescribing statin ther-
apy to reduce LDL cholesterol levels (44). At present,
however, guidelines do not exist for using vascular stiff-
ness measures as surrogate end points for treatment in
primary or secondary prevention strategies that involve
patients with IFG or diabetes. Further study is needed to
explore this issue.
Because individuals with IFG and diabetes often exhibit
reduced exercise capacity (45,46), our results indicate that
mechanisms other than abnormalities of aortic stiffness
such as higher myocardial oxygen consumption at rest, an
inability to adapt coronary ﬂow adequately to higher
metabolic demands during peak exercise, or abnormal
peripheral arterial endothelial function may be more likely
responsible for exercise intolerance in middle-aged and
older individuals with IFG (45,46).
The investigators from the Hoorn Study (8) have re-
ported that subjects with impaired glucose tolerance and
diabetes had arterial stiffening in both the central and
peripheral arterial system and that central arterial stiffness
of those with impaired glucose tolerance was intermediate
in severity between the group with normal glucose toler-
ance and diabetes. Our study had a similar ﬁnding on
peripheral arterial stiffening, but our measure of aortic
distensibility arterial stiffness was not increased in those
with IFG. There are possible explanations on the differ-
ence of this ﬁnding. The criteria for classiﬁcation of
subjects with impaired glucose metabolism were different
in our study and the Hoorn Study. Our study used fasting
glucose according to the American Diabetes Association
criteria, but the Hoorn Study deﬁned glucose tolerance
according to the WHO criteria. Subjects with IFG (Amer-
ican Diabetes Association criteria) and impaired glucose
tolerance (WHO criteria) are not identical, and the patho-
physiology of the disorders are different. When comparing
subjects with IFG with those with impaired glucose toler-
ance, those with IFG are more strongly correlated with
insulin resistance, whereas impaired glucose tolerance is
more strongly correlated to impaired insulin secretion
(47,48).
Aortic stiffness was measured differently in the two
studies. Our study used aortic distensibility, whereas the
Hoorn Study used aortic augmentation index. Aortic dis-
tensibility measures stiffness in the proximal ascending
thoracic aorta, which has direct implications for stimulat-
ing LV hypertrophy; aortic augmentation index measures
stiffness within the entire aorta. This latter value seems
more similar to the assessment of total vascular stiffness
that we report currently. We noted differences in total
arterial stiffness among NFG, IFG, and diabetes (similar to
the Hoorn results). Third, participants in the Hoorn Study
were on average older than ours. Age is an important
inﬂuence on aortic stiffening; stiffening within the cardio-
vascular system increases with age.
Our study has the following limitations. Up to 5% of
subjects with IFG exhibit diabetes if they undergo 2-h
glucose tolerance testing. Because those with diabetes
exhibit stiffer arteries than those with IFG, it stands to
reason that moving 5% of the IFG participants who are
truly diabetic into the diabetes group would further reduce
differences between our NFG and IFG groups. Brachial
cuff pressure, rather than an invasive measure of central
aortic pressure, was used in our calculations of total and
proximal thoracic aortic stiffness. Our noninvasive deter-
minations of arterial stiffness (ratios involving pulse pres-
sure) are based on the principle that in a steady-state
condition, the arterial tree can be modeled as an elastic
chamber with a constant compliance (49). Although these
measures have been validated with standard invasive
assessment of arterial compliance in animals (50) and
humans (21) and have been shown to be an independent
predictor for cardiovascular death (21), younger, healthier
individuals may have more ampliﬁcation of PP than older
individuals. To provide for this possibility, we accounted
for age in our statistical models. The difference we observe
between our IFG and NFG groups is present in our total
arterial stiffness measure, but not in our aortic distensibil-
ity measure. This observation suggests that the lack of
difference between NFG and IFG in aortic distensibility is
in fact true. Also, LV mass, which parallels proximal
thoracic stiffness, is not different in the NFG and IFG
groups. Our LV mass determination does not involve PP.
It is important to recognize that our results reﬂect those
generated from participants aged 45 to 85 years of age. We
are uncertain of the effects of IFG and diabetes on stiffness
parameters in individuals including children, teenagers,
and younger adults.
In conclusion, in middle-aged and older adults, the
pre-diabetes state of IFG is associated with an increase in
arterial stiffening that primarily impacts regions exclusive
of the ascending thoracic aorta. Perhaps prevention of
diabetes in those with IFG would be associated with
preservation of more favorable heart weight and proximal
thoracic aortic distensibility, which are known risk factors
for adverse cardiac events.
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